Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PACB 
Pacific Biosciences of California (PACB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: PACB (1-star) is a SELL. SELL since 2 days. Profits (-6.20%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $2.15
1 Year Target Price $2.15
| 5 | Strong Buy |
| 1 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.23% | Avg. Invested days 32 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 363.45M USD | Price to earnings Ratio - | 1Y Target Price 2.15 |
Price to earnings Ratio - | 1Y Target Price 2.15 | ||
Volume (30-day avg) 14 | Beta 2.17 | 52 Weeks Range 0.85 - 2.72 | Updated Date 08/13/2025 |
52 Weeks Range 0.85 - 2.72 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.1731 | Actual -0.13 |
Profitability
Profit Margin - | Operating Margin (TTM) -112.73% |
Management Effectiveness
Return on Assets (TTM) -33.28% | Return on Equity (TTM) -189.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 747934439 | Price to Sales(TTM) 2.33 |
Enterprise Value 747934439 | Price to Sales(TTM) 2.33 | ||
Enterprise Value to Revenue 4.79 | Enterprise Value to EBITDA -4.15 | Shares Outstanding 300371008 | Shares Floating 298168894 |
Shares Outstanding 300371008 | Shares Floating 298168894 | ||
Percent Insiders 9.06 | Percent Institutions 61.79 |
Upturn AI SWOT
Pacific Biosciences of California
Company Overview
History and Background
Pacific Biosciences of California, Inc. (PacBio) was founded in 2004. It focuses on designing, developing, and manufacturing advanced sequencing systems to resolve genetically complex problems. Their key milestones include the development of Single Molecule, Real-Time (SMRT) sequencing technology and subsequent platform releases.
Core Business Areas
- Sequencing Systems: Development and sale of sequencing instruments, including the Revio, Sequel IIe, and Onso systems. These instruments are used for various applications, including genome assembly, structural variant detection, and epigenetics.
- Consumables: Sale of consumables required for running sequencing experiments, such as SMRT cells, reagents, and library preparation kits.
- Service and Support: Providing service and support contracts to customers, as well as training and application support.
Leadership and Structure
Christian Henry serves as President and CEO. The company has a typical corporate structure with functional departments such as Research & Development, Sales & Marketing, Operations, and Finance.
Top Products and Market Share
Key Offerings
- Revio: A high-throughput long-read sequencing system. Market share is difficult to pinpoint exactly but PacBio is trying to significantly expand their market share. Competitors: Illumina, Oxford Nanopore Technologies.
- Sequel IIe: A mid-throughput long-read sequencing system. Similar market share dynamics to Revio. Competitors: Illumina, Oxford Nanopore Technologies.
- Onso: A short-read sequencing system, that broadens the company's capabilities. Competitors: Illumina, Complete Genomics (MGI Tech).
Market Dynamics
Industry Overview
The genomics market is experiencing significant growth driven by increasing demand for personalized medicine, drug discovery, and agricultural applications. Sequencing technologies are constantly evolving, with long-read sequencing gaining traction.
Positioning
PacBio is positioned as a leader in long-read sequencing, offering high accuracy and long read lengths. They are differentiated by their SMRT technology, which provides unique advantages for certain applications. They are expanding into short-read sequencing.
Total Addressable Market (TAM)
The total addressable market is estimated to be in the tens of billions of dollars. PacBio aims to capture a larger share of this market through technological advancements and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Long-read sequencing technology leadership
- High accuracy sequencing data
- Strong brand reputation in specific applications
- Expanding product portfolio
Weaknesses
- Higher cost per base compared to short-read sequencing
- Smaller installed base compared to Illumina
- Reliance on specific market segments
- Profitability challenges
Opportunities
- Growing demand for long-read sequencing
- Expansion into new markets (e.g., clinical diagnostics)
- Development of new applications for SMRT technology
- Partnerships with pharmaceutical companies and research institutions
Threats
- Competition from Illumina and Oxford Nanopore Technologies
- Technological advancements by competitors
- Economic downturn affecting research funding
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- ILMN
- ONT.L
Competitive Landscape
PacBio differentiates itself through long-read sequencing, while Illumina dominates short-read sequencing. Oxford Nanopore Technologies provides real-time, long-read sequencing, creating a competitive landscape with varying strengths and weaknesses.
Major Acquisitions
Circulomics
- Year: 2021
- Acquisition Price (USD millions): 80
- Strategic Rationale: Acquisition of Circulomics was made to enhance PacBio's sample preparation workflow for long-read sequencing.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by periods of rapid innovation followed by commercialization challenges.
Future Projections: Analysts expect revenue growth to accelerate with the adoption of new platforms, and profitability to improve over time.
Recent Initiatives: Recent initiatives include the launch of the Revio and Onso systems, strategic partnerships, and expansion of their commercial team.
Summary
PacBio is a key player in the long-read sequencing market with innovative technology and expanding product offerings. While facing competition from larger companies, PacBio is poised for growth with its Revio and Onso platforms. Continued commercial execution and strategic partnerships are critical to realizing its full potential. Investors should watch for improvements in profitability and market share gains.
Peer Comparison
Sources and Disclaimers
Data Sources:
- PacBio Investor Relations
- SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pacific Biosciences of California
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2010-10-27 | President, CEO & Director Mr. Christian O. Henry M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 575 | Website https://www.pacb.com |
Full time employees 575 | Website https://www.pacb.com | ||
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.